NCT03970798View on ClinicalTrials.gov

A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 22, 2019

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
Parkinson's Disease
Interventions
DRUG

Midazolam

In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.

DRUG

Caffeine

In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.

DRUG

Rosuvastatin

In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.

DRUG

KW-6356

In Period 2, Day 4-13(except Day11) a single dose of KW-6356 will be administered after breakfast, Day 11 a single dose of KW-6356 will be administered after fasting for at least 10 hours.

Trial Locations (1)

Unknown

Fukuoka Mirai Hospital Clinical Research Center, Fukuoka

All Listed Sponsors
lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT03970798 - A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin | Biotech Hunter | Biotech Hunter